Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution

MLA

Jeffrey P. Hammel, et al. “Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution.” Antimicrobial Agents and Chemotherapy, vol. 64, no. 10, Dec. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....025e09a6747958717fc457a0d8d9aae1&authtype=sso&custid=ns315887.

APA

Jeffrey P. Hammel, Elizabeth A Lakota, Yu Nagira, Paul G. Ambrose, Kenichiro Kondo, Nobuo Sato, M Courtney Safir, Sujata M. Bhavnani, Tomokazu Koresawa, Brian VanScoy, & Christopher M. Rubino. (2019). Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution. Antimicrobial Agents and Chemotherapy, 64(10).

Chicago

Jeffrey P. Hammel, Elizabeth A Lakota, Yu Nagira, Paul G. Ambrose, Kenichiro Kondo, Nobuo Sato, M Courtney Safir, et al. 2019. “Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution.” Antimicrobial Agents and Chemotherapy 64 (10). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....025e09a6747958717fc457a0d8d9aae1&authtype=sso&custid=ns315887.